| Revision as of 21:55, 25 May 2018 editVioletriga (talk | contribs)Extended confirmed users37,361 edits as you like SBM so much I'm sure that this content is acceptable to you← Previous edit | Revision as of 22:31, 25 May 2018 edit undoJytdog (talk | contribs)Autopatrolled, Extended confirmed users, Pending changes reviewers, Rollbackers187,951 edits Undid revision 842963623 by Violetriga (talk) you are "sure". Giving edit war warning. This aggressive behavior needs to stop.Tag: UndoNext edit → | ||
| Line 3: | Line 3: | ||
| Evidence from two large studies in 2017 showed that the transfusion of blood from younger donors to older people was either no different from, or led to worse outcomes than, blood from older donors.<ref name=sbm>{{cite news|last1=Novella|first1=Steven|title=Parabiosis – The Next Snakeoil|url=https://sciencebasedmedicine.org/parabiosis-the-next-snakeoil/|work=Science-Based Medicine|date=3 August 2016}}</ref><ref name=Garraud2017>{{cite journal|last1=Garraud|first1=O|title=Younger blood from older donors: Admitting ignorance and seeking stronger data and clinical trials?|journal=Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis|date=August 2017|volume=56|issue=4|pages=635-636|doi=10.1016/j.transci.2017.07.002|pmid=28780993}}</ref> Research on blood transfusion outcomes has been complicated by the lack of careful characterization of the transfusion products that have been used in clinical trials; studies had focused on how storage methods and duration might affect blood, but not on the differences among lots of blood themselves.<ref>{{cite journal|last1=Ning|first1=S|last2=Heddle|first2=NM|last3=Acker|first3=JP|title=Exploring donor and product factors and their impact on red cell post-transfusion outcomes.|journal=Transfusion medicine reviews|date=January 2018|volume=32|issue=1|pages=28-35|doi=10.1016/j.tmrv.2017.07.006|pmid=28988603}}</ref> | Evidence from two large studies in 2017 showed that the transfusion of blood from younger donors to older people was either no different from, or led to worse outcomes than, blood from older donors.<ref name=sbm>{{cite news|last1=Novella|first1=Steven|title=Parabiosis – The Next Snakeoil|url=https://sciencebasedmedicine.org/parabiosis-the-next-snakeoil/|work=Science-Based Medicine|date=3 August 2016}}</ref><ref name=Garraud2017>{{cite journal|last1=Garraud|first1=O|title=Younger blood from older donors: Admitting ignorance and seeking stronger data and clinical trials?|journal=Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis|date=August 2017|volume=56|issue=4|pages=635-636|doi=10.1016/j.transci.2017.07.002|pmid=28780993}}</ref> Research on blood transfusion outcomes has been complicated by the lack of careful characterization of the transfusion products that have been used in clinical trials; studies had focused on how storage methods and duration might affect blood, but not on the differences among lots of blood themselves.<ref>{{cite journal|last1=Ning|first1=S|last2=Heddle|first2=NM|last3=Acker|first3=JP|title=Exploring donor and product factors and their impact on red cell post-transfusion outcomes.|journal=Transfusion medicine reviews|date=January 2018|volume=32|issue=1|pages=28-35|doi=10.1016/j.tmrv.2017.07.006|pmid=28988603}}</ref> | ||
| The evidence suggesting the treatment could be beneficial was based on research done on rodents at ] in which blood transfused from young mice seemed to invigorate older mice |
The evidence suggesting the treatment could be beneficial was based on research done on rodents at ] in which blood transfused from young mice seemed to invigorate older mice;<ref name=Garraud2017/> the circulatory systems of the mice were connected which put them in a state of ].<ref name=sbm/> A company, Alkahest, was spun out of Stanford based on that work, and as of 2017 was collaborating with European pharmaceutical company ] to create a ]-based experimental ] drug, which they propose to test on people with ].<ref name=Trends2017>{{cite journal|last1=de Magalhães|first1=JP|last2=Stevens|first2=M|last3=Thornton|first3=D|title=The Business of Anti-Aging Science.|journal=Trends in biotechnology|date=November 2017|volume=35|issue=11|pages=1062-1073|doi=10.1016/j.tibtech.2017.07.004|pmid=28778607}} {{open access}}</ref><ref>{{cite journal|last1=Drew|first1=L|title=Neuroscience: The power of plasma.|journal=Nature|date=27 September 2017|volume=549|issue=7673|pages=S26-S27|doi=10.1038/549S26a|pmid=28953857}}</ref> | ||
| A company, Alkahest, was spun out of Stanford based on that work, and as of 2017 was collaborating with European pharmaceutical company ] to create a ]-based experimental ] drug, which they propose to test on people with ].<ref name=Trends2017>{{cite journal|last1=de Magalhães|first1=JP|last2=Stevens|first2=M|last3=Thornton|first3=D|title=The Business of Anti-Aging Science.|journal=Trends in biotechnology|date=November 2017|volume=35|issue=11|pages=1062-1073|doi=10.1016/j.tibtech.2017.07.004|pmid=28778607}} {{open access}}</ref><ref>{{cite journal|last1=Drew|first1=L|title=Neuroscience: The power of plasma.|journal=Nature|date=27 September 2017|volume=549|issue=7673|pages=S26-S27|doi=10.1038/549S26a|pmid=28953857}}</ref> | |||
| A startup company named Ambrosia has been selling "young blood transfusions" for $8,000 since 2017 under the guise of running a ], to see if such transfusions lead to changes in the blood of recipients.<ref name=sbm/><ref name=Trends2017/><ref>{{cite news|last1=Haynes|first1=Gavin|title=Ambrosia: the startup harvesting the blood of the young|url=https://www.theguardian.com/society/shortcuts/2017/aug/21/ambrosia-the-startup-harvesting-the-blood-of-the-young|accessdate=23 May 2018|work=The Guardian|date=21 August 2017|language=en}}</ref> | A startup company named Ambrosia has been selling "young blood transfusions" for $8,000 since 2017 under the guise of running a ], to see if such transfusions lead to changes in the blood of recipients.<ref name=sbm/><ref name=Trends2017/><ref>{{cite news|last1=Haynes|first1=Gavin|title=Ambrosia: the startup harvesting the blood of the young|url=https://www.theguardian.com/society/shortcuts/2017/aug/21/ambrosia-the-startup-harvesting-the-blood-of-the-young|accessdate=23 May 2018|work=The Guardian|date=21 August 2017|language=en}}</ref> | ||
Revision as of 22:31, 25 May 2018
Young blood transfusion refers to transfusing blood specifically from a young person into an older person with the intention of creating a medicinal benefit.
Evidence from two large studies in 2017 showed that the transfusion of blood from younger donors to older people was either no different from, or led to worse outcomes than, blood from older donors. Research on blood transfusion outcomes has been complicated by the lack of careful characterization of the transfusion products that have been used in clinical trials; studies had focused on how storage methods and duration might affect blood, but not on the differences among lots of blood themselves.
The evidence suggesting the treatment could be beneficial was based on research done on rodents at Stanford University in which blood transfused from young mice seemed to invigorate older mice; the circulatory systems of the mice were connected which put them in a state of parabiosis. A company, Alkahest, was spun out of Stanford based on that work, and as of 2017 was collaborating with European pharmaceutical company Grifols to create a blood plasma-based experimental biologic drug, which they propose to test on people with Alzheimer's.
A startup company named Ambrosia has been selling "young blood transfusions" for $8,000 since 2017 under the guise of running a clinical trial, to see if such transfusions lead to changes in the blood of recipients.
Human trials are reported to be underway in China and Korea but with very little detail about what is actually involved.
References
- ^ Novella, Steven (3 August 2016). "Parabiosis – The Next Snakeoil". Science-Based Medicine.
- ^ Garraud, O (August 2017). "Younger blood from older donors: Admitting ignorance and seeking stronger data and clinical trials?". Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis. 56 (4): 635–636. doi:10.1016/j.transci.2017.07.002. PMID 28780993.
- Ning, S; Heddle, NM; Acker, JP (January 2018). "Exploring donor and product factors and their impact on red cell post-transfusion outcomes". Transfusion medicine reviews. 32 (1): 28–35. doi:10.1016/j.tmrv.2017.07.006. PMID 28988603.
- ^ de Magalhães, JP; Stevens, M; Thornton, D (November 2017). "The Business of Anti-Aging Science". Trends in biotechnology. 35 (11): 1062–1073. doi:10.1016/j.tibtech.2017.07.004. PMID 28778607.
- Drew, L (27 September 2017). "Neuroscience: The power of plasma". Nature. 549 (7673): S26 – S27. doi:10.1038/549S26a. PMID 28953857.
- Haynes, Gavin (21 August 2017). "Ambrosia: the startup harvesting the blood of the young". The Guardian. Retrieved 23 May 2018.
- Bercovici, Jeff. "Peter Thiel Is Very, Very Interested In Young People's Blood". Inc. Retrieved 5 May 2018.